A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
复制标题

DOI:
10.3346/jkms.2021.36.e306
复制
发表时间:
2021-11-08
影响因子:
4.5
通讯作者:
Lee KH
Lee KH
中科院分区:
医学4区
文献类型:
--
作者:
Kim G;Choi EJ;Park HS;Lee JH;Lee JH;Lee KH

文献摘要

参考文献

被引文献

相似文献

免疫性血小板减少症(ITP)是一种自身免疫性疾病,其特征是通过抗体介导的机制破坏血小板。ITP是冠状病毒疾病的表现之一,也是严重急性呼吸道综合征冠状病毒2(SARS-CoV-2)疫苗接种后发生的不良事件。在接种两种基于mRNA的疫苗-BTN 162 b2(Pfizer-BioNTech)和mRNA-1273(Moderna)-后,已经描述了几例ITP病例。在此,我们报告一例在韩国接种ChAdOx 1腺病毒载体nCoV-19(阿斯利康)疫苗后发生的ITP。一名66岁女性在接受ChAdOx 1 nCoV-19首次给药后3天出现上下肢多发性瘀斑和牙龈出血。她的实验室检查结果显示孤立的重度血小板减少症,无合并凝血病的证据。她被诊断为ITP,并成功地用大剂量地塞米松和静脉注射免疫球蛋白治疗。临床怀疑确定疫苗相关ITP对于及时启动适当治疗非常重要。
Immune thrombocytopenia (ITP) is an autoimmune condition characterized by platelet destruction through antibody-mediated mechanism. ITP is one of the manifestations of a coronavirus disease, as well as an adverse event occurring after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several cases of ITP have been described after vaccination with two mRNA-based vaccines—BTN162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)—against SARS-CoV-2. Herein, we report a case of ITP occurring after vaccination with ChAdOx1 adenovirus vector nCoV-19 (AstraZeneca) vaccine in Korea. A 66-year-old woman presented with multiple ecchymoses on both upper and lower extremities and gingival bleeding, appearing 3 days after receiving the first dose of ChAdOx1 nCoV-19. Her laboratory results showed isolated severe thrombocytopenia without evidence of combined coagulopathy. She was diagnosed with ITP and successfully treated with high-dose dexamethasone and intravenous immunoglobulin. Clinical suspicion to identify vaccine-related ITP is important to promptly initiate appropriate treatment.
DOI: 10.7759/cureus.14099
发表时间: 2021-03-25
期刊: Cureus
影响因子: --
作者:
Malayala SV;Mohan G;Vasireddy D;Atluri P
通讯作者: Atluri P
DOI: 10.1056/nejmoa2104840
发表时间: 2021-06-03
期刊: The New England journal of medicine
影响因子: --
作者:
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者: Eichinger S
DOI: 10.1007/s42399-020-00521-8
发表时间: 2020
期刊: SN comprehensive clinical medicine
影响因子: --
作者:
Bhattacharjee S;Banerjee M
通讯作者: Banerjee M
DOI: 10.1136/bcr-2021-242220
发表时间: 2021-05-31
期刊: BMJ case reports
影响因子: 0.9
作者:
Fueyo-Rodriguez O;Valente-Acosta B;Jimenez-Soto R;Neme-Yunes Y;Inclán-Alarcón SI;Trejo-Gonzalez R;García-Salcido MÁ
通讯作者: García-Salcido MÁ
DOI: 10.2147/jbm.s307047
发表时间: 2021
影响因子: 2
作者:
Helms JM;Ansteatt KT;Roberts JC;Kamatam S;Foong KS;Labayog JS;Tarantino MD
通讯作者: Tarantino MD